Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal Care
STAINES-UPON-THAMES, United Kingdom, 19 May 2017 -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today marked the donation of £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust at St Peter’s Hospital in Chertsey, outside London.
Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, remarked: “This donation demonstrates our commitment to supporting local healthcare providers and the important work they do with the patient community, a community of which we are proud to be a part.” Mallinckrodt recently opened its Global Corporate headquarters in nearby Staines-upon-Thames.
Aileen McLeish, Chairman of Ashford and St. Peter’s Hospitals NHS Foundation Trust thanked Mallinckrodt for the donation, which will help support the important work undertaken by the Trust’s Neonatal Intensive Care Unit.
“On behalf of the Trust, I would like to thank Mallinckrodt for their extremely generous donation and for their interest in Ashford and St Peter’s Hospitals. We are always keen to forge positive links with the local business community and look forward to developing our relationship with Mallinckrodt further in the future.”
Ashford and St. Peter’s Hospitals NHS Foundation Trust is the largest provider of acute hospital services in Surrey and provides a high-quality service to more than 380,000 people in the boroughs of Runnymede, Spelthorne, Woking and parts of Elmbridge, Hounslow, Surrey Heath and beyond.
Welcoming the donation, Runnymede and Weybridge MP Philip Hammond commented: “This generous donation by Mallinckrodt will enable the Neonatal Intensive Care Unit at Ashford and St. Peter’s NHS Trust to continue with their invaluable work, offering life-saving care to ill or premature babies, and giving hope to hundreds of families. I know that I speak on behalf of the entire community in welcoming the company to the area.”
Spelthorne MP Kwasi Kwarteng, who opened Mallinckrodt’s Global Corporate headquarters in Staines-upon-Thames, added: “Mallinckrodt’s wonderful contribution to our local hospital shows their great commitment to our community. We all hope this is the beginning of a close relationship.”
After the ceremony, Dr. Paul Crawshaw, Divisional Director for Women and Children’s Services and Consultant Neonatologist showed Mr. Trudeau around the Neonatal Intensive Care Unit at St. Peter’s Hospital. He explained how the donation will help support the Unit’s vital work in particular with specialist training for nursing staff in areas such as pathophysiology, pharmacology, advanced medicines management and life support.
About Mallinckrodt plc
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and haemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines, and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
The Henley Group
+44 1491 570 971
Senior Communications Manager
Chief Public Affairs Officer
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations
Vice President, Government Affairs and Policy